Eyenovia Liabilities And Stockholders Equity from 2010 to 2025

EYEN Stock  USD 1.69  0.03  1.74%   
Eyenovia Liabilities And Stockholders Equity yearly trend continues to be very stable with very little volatility. Liabilities And Stockholders Equity is likely to drop to about 21 M. Liabilities And Stockholders Equity is the total of all liabilities and equity in the company, which should equal Eyenovia's total assets according to the accounting equation. View All Fundamentals
 
Liabilities And Stockholders Equity  
First Reported
2016-12-31
Previous Quarter
19 M
Current Value
22.8 M
Quarterly Volatility
10 M
 
Covid
Check Eyenovia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyenovia's main balance sheet or income statement drivers, such as Interest Income of 661.2 K, Depreciation And Amortization of 945.7 K or Interest Expense of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.7 M, Dividend Yield of 0.0 or PTB Ratio of 1.2 K. Eyenovia financial statements analysis is a perfect complement when working with Eyenovia Valuation or Volatility modules.
  
Check out the analysis of Eyenovia Correlation against competitors.
To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.

Latest Eyenovia's Liabilities And Stockholders Equity Growth Pattern

Below is the plot of the Liabilities And Stockholders Equity of Eyenovia over the last few years. It is the total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation. Eyenovia's Liabilities And Stockholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eyenovia's overall financial position and show how it may be relating to other accounts over time.
Liabilities And Stockholders Equity10 Years Trend
Slightly volatile
   Liabilities And Stockholders Equity   
14.733.931.731.028.833.121.0131%-7%-2%-7%15%-36%100%
       Timeline  

Eyenovia Liabilities And Stockholders Equity Regression Statistics

Arithmetic Mean15,012,372
Geometric Mean9,015,591
Coefficient Of Variation87.41
Mean Deviation11,803,460
Median14,697,619
Standard Deviation13,121,752
Sample Variance172.2T
Range31.1M
R-Value0.86
Mean Square Error48.1T
R-Squared0.74
Significance0.000019
Slope2,370,119
Total Sum of Squares2582.7T

Eyenovia Liabilities And Stockholders Equity History

202521 M
202433.1 M
202328.8 M
202231 M
202131.7 M
202033.9 M
201914.7 M

About Eyenovia Financial Statements

Eyenovia investors utilize fundamental indicators, such as Liabilities And Stockholders Equity, to predict how Eyenovia Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Liabilities And Stockholders Equity33.1 M21 M

Pair Trading with Eyenovia

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eyenovia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will appreciate offsetting losses from the drop in the long position's value.

Moving together with Eyenovia Stock

  0.68EXAS EXACT SciencesPairCorr

Moving against Eyenovia Stock

  0.82OPT OptheaPairCorr
  0.7LTRN Lantern PharmaPairCorr
  0.69VERV Verve TherapeuticsPairCorr
  0.64FENC Fennec PharmaceuticalsPairCorr
  0.45GANX Gain TherapeuticsPairCorr
The ability to find closely correlated positions to Eyenovia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyenovia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyenovia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyenovia to buy it.
The correlation of Eyenovia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyenovia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyenovia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eyenovia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Eyenovia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eyenovia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eyenovia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eyenovia Stock:
Check out the analysis of Eyenovia Correlation against competitors.
To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(55.20)
Revenue Per Share
0.047
Quarterly Revenue Growth
0.356
Return On Assets
(0.80)
Return On Equity
(3.88)
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

RVPHW
Reviva Pharmaceuticals
0.13  -0.01  -7.14 
CDTX
Cidara Therapeutics
24.90  1.05  4.40 
RVPH
Reviva Pharmaceuticals
1.44  0.01  0.70 
OCUL
Ocular Therapeutix
7.14  0.20  2.88 
News Freq…Investor S…